Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tulobuterol is a long-acting beta2-adrenergic receptor agonist used primarily as a bronchodilator for the management of asthma and chronic obstructive pulmonary disease (COPD). It works by selectively stimulating beta2-adrenergic receptors in bronchial smooth muscle, leading to muscle relaxation and airway dilation. This results in improved airflow and relief from symptoms such as wheezing, shortness of breath, and chest tightness. Tulobuterol is notable for its availability as a transdermal patch (Hokunalin tape), which provides sustained drug delivery over 24 hours with once-daily application. The patch formulation helps synchronize peak blood concentrations with periods of greatest need (e.g., morning dip in respiratory function) while minimizing systemic side effects[1][3][8]. Oral tablet forms are also available in some regions[6]. Tulobuterol has been approved since 1998 in Japan and is marketed in several countries including Japan, Germany, China, South Korea, Bangladesh, Pakistan, Venezuela, and India[3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tulobuterol.